Advertisement

Taurine 10 pp 703-716 | Cite as

Taurine Administration Mitigates Cisplatin Induced Acute Nephrotoxicity by Decreasing DNA Damage and Inflammation: An Immunocytochemical Study

  • Masahiro Tsunekawa
  • Shumin Wang
  • Toshihiro Kato
  • Takenori Yamashita
  • Ning MaEmail author
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 975)

Abstract

Cisplatin (CDDP) is one of the most effective chemotherapeutic agent used in the treatment of many kind of solid tumors. Its primary side effect is nephrotoxicity. The aim of this study to investigate the effects of taurine on cisplatin-induced acute nephrotoxicity. A single intraperitoneal injection of CDDP (15 mg/kg, or 25 mg/kg) deteriorated the kidney functions as reflected by histopathological changes. Histopathological changes were observed in all cisplatin groups. In the cisplatin group, oxidative stress was evident in the cisplatin group by observing an increase in 8-OHdG expression, an indicator of oxidative DNA damage. CDDP also resulted to an increase in CD68 expression in the renal tissues of CDDP groups. Taurine transporter (TauT) was down-regulated, and p53 was up-regulated in renal tissues as indicated by immunohistochemical analysis. Administration with taurine prior to a cisplatin injection was able to protect against deterioration of kidney function, to abrogate the decline in anti-oxidants and to suppress the increase in DNA damage. Moreover, taurine inhibited p53 activation and improved the pathological changes induced by cisplatin. This study demonstrates the protective effects of taurine in attenuating the expression of pro-inflammatory mediators and in improving antioxidant capacity in the kidney of cisplatin-injected rats. Thus, taurine could be a beneficial dietary supplement to attenuate cisplatin induced nephrotoxicity.

Keywords

Cisplatin Nephrotoxicity Oxidation Inflammation Immunocytochemistry 

Abbreviations

8-OHdG

8-Hydroxy-2′-deoxyguanosine

CDDP

Cis-diammine dichloroplatinum II (cisplatin)

TauT

Taurine transporter

References

  1. Arany I, Safirstein RL (2003) Cisplatin nephrotoxicity. Semin Nephrol 23(5):460–464. S0270929503000895 [pii]CrossRefPubMedGoogle Scholar
  2. Camano S, Lazaro A, Moreno-Gordaliza E, Torres AM, de Lucas C, Humanes B, Lazaro JA, Milagros Gomez-Gomez M, Bosca L, Tejedor A (2010) Cilastatin attenuates cisplatin-induced proximal tubular cell damage. J Pharmacol Exp Ther 334(2):419–429. doi: 10.1124/jpet.110.165779. jpet.110.165779 [pii]CrossRefPubMedGoogle Scholar
  3. Chirino YI, Pedraza-Chaverri J (2009) Role of oxidative and nitrosative stress in cisplatin-induced nephrotoxicity. Exp Toxicol Pathol 61(3):223–242. doi: 10.1016/j.etp.2008.09.003. S0940-2993(08)00138-3 [pii]CrossRefPubMedGoogle Scholar
  4. Davis CA, Nick HS, Agarwal A (2001) Manganese superoxide dismutase attenuates Cisplatin-induced renal injury: importance of superoxide. J Am Soc Nephrol 12(12):2683–2690PubMedGoogle Scholar
  5. Faubel S, Lewis EC, Reznikov L, Ljubanovic D, Hoke TS, Somerset H, Oh DJ, Lu L, Klein CL, Dinarello CA, Edelstein CL (2007) Cisplatin-induced acute renal failure is associated with an increase in the cytokines interleukin (IL)-1beta, IL-18, IL-6, and neutrophil infiltration in the kidney. J Pharmacol Exp Ther 322(1):8–15. doi: 10.1124/jpet.107.119792. jpet.107.119792 [pii]CrossRefPubMedGoogle Scholar
  6. Fontanelli R, Spatti G, Raspagliesi F, Zunino F, Di Re F (1992) A preoperative single course of high-dose cisplatin and bleomycin with glutathione protection in bulky stage IB/II carcinoma of the cervix. Ann Oncol 3(2):117–121CrossRefPubMedGoogle Scholar
  7. Francescato HD, Costa RS, Scavone C, Coimbra TM (2007) Parthenolide reduces cisplatin-induced renal damage. Toxicology 230(1):64–75. doi: 10.1016/j.tox.2006.10.025. S0300-483X(06)00638-X [pii]CrossRefPubMedGoogle Scholar
  8. Giri SN, Gurujeyalakshmi G, Wang Y (2000) Suppression of bleomycin-induced increased production of nitric oxide and NF-kB activation by treatment with taurine and niacin. Adv Exp Med Biol 483:545–561. doi: 10.1007/0-306-46838-7_59 CrossRefPubMedGoogle Scholar
  9. Han X, Chesney RW (2010) Stress-responsive gene TauT and acute kidney injury. J Biomed Sci 17(Suppl 1):S28. doi: 10.1186/1423-0127-17-S1-S28. 1423-0127-17-S1-S28 [pii]CrossRefPubMedPubMedCentralGoogle Scholar
  10. Han X, Patters AB, Jones DP, Zelikovic I, Chesney RW (2006) The taurine transporter: mechanisms of regulation. Acta Physiol (Oxford) 187(1–2):61–73. doi: 10.1111/j.1748-1716.2006.01573.x. APS1573 [pii]CrossRefGoogle Scholar
  11. Hansen SH, Andersen ML, Birkedal H, Cornett C, Wibrand F (2006) The important role of taurine in oxidative metabolism. Adv Exp Med Biol 583:129–135CrossRefPubMedGoogle Scholar
  12. Hosokawa Y, Matsumoto A, Oka J, Itakura H, Yamaguchi K (1990) Isolation and characterization of a cDNA for rat liver cysteine dioxygenase. Biochem Biophys Res Commun 168(2):473–478. 0006-291X(90)92345-Z [pii]CrossRefPubMedGoogle Scholar
  13. Ideishi M, Miura S, Sakai T, Sasaguri M, Misumi Y, Arakawa K (1994) Taurine amplifies renal kallikrein and prevents salt-induced hypertension in Dahl rats. J Hypertens 12(6):653–661CrossRefPubMedGoogle Scholar
  14. Kim C, Choi HS, Kim JW (2006) Taurine chloramine inhibits the production of nitric oxide and superoxide anion by modulating specific mitogen-activated protein kinases. Adv Exp Med Biol 583:493–498CrossRefPubMedGoogle Scholar
  15. Lambert IH, Kristensen DM, Holm JB, Mortensen OH (2014) Physiological role of taurine--from organism to organelle. Acta Physiol (Oxford) 213(1):191–212. doi: 10.1111/apha.12365 CrossRefGoogle Scholar
  16. Loehrer PJ, Einhorn LH (1984) Drugs five years later. Cisplatin Ann Intern Med 100(5):704–713CrossRefPubMedGoogle Scholar
  17. Ma N, Aoki E, Semba R (1994) An immunohistochemical study of aspartate, glutamate, and taurine in rat kidney. J Histochem Cytochem 42(5):621–626CrossRefPubMedGoogle Scholar
  18. Mochizuki T, Satsu H, Shimizu M (2005) Signaling pathways involved in tumor necrosis factor alpha-induced upregulation of the taurine transporter in Caco-2 cells. FEBS Lett 579(14):3069–3074. doi: 10.1016/j.febslet.2005.04.063. S0014-5793(05)00540-5 [pii]CrossRefPubMedGoogle Scholar
  19. Mozaffari MS, Patel C, Abdelsayed R, Schaffer SW (2006) Accelerated NaCl-induced hypertension in taurine-deficient rat: role of renal function. Kidney Int 70(2):329–337. doi: 10.1038/sj.ki.5001503. S0085-2538(15)51923-6 [pii]CrossRefPubMedGoogle Scholar
  20. Ozols RF (1995) Current status of chemotherapy for ovarian cancer. Semin Oncol 22(5 Suppl 12):61–66PubMedGoogle Scholar
  21. Pabla N, Dong Z (2008) Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int 73(9):994–1007. doi: 10.1038/sj.ki.5002786. 5002786 [pii]CrossRefPubMedGoogle Scholar
  22. Panici PB, Greggi S, Scambia G, Ragusa G, Baiocchi G, Battaglia F, Coronetta F, Mancuso S (1991) High-dose cisplatin and bleomycin neoadjuvant chemotherapy plus radical surgery in locally advanced cervical carcinoma: a preliminary report. Gynecol Oncol 41(3):212–216. 0090-8258(91)90310-2 [pii]CrossRefPubMedGoogle Scholar
  23. Perez-Rojas JM, Guerrero-Beltran CE, Cruz C, Sanchez-Gonzalez DJ, Martinez-Martinez CM, Pedraza-Chaverri J (2011) Preventive effect of tert-butylhydroquinone on cisplatin-induced nephrotoxicity in rats. Food Chem Toxicol 49(10):2631–2637. doi: 10.1016/j.fct.2011.07.008. S0278-6915(11)00331-0 [pii]CrossRefPubMedGoogle Scholar
  24. Ries F, Klastersky J (1986) Nephrotoxicity induced by cancer chemotherapy with special emphasis on cisplatin toxicity. Am J Kidney Dis 8(5):368–379. S0272638686001129 [pii]CrossRefPubMedGoogle Scholar
  25. Sato S, Yamate J, Saito T, Hosokawa T, Saito S, Kurasaki M (2002) Protective effect of taurine against renal interstitial fibrosis of rats induced by cisplatin. Naunyn Schmiedeberg’s Arch Pharmacol 365(4):277–283. doi: 10.1007/s00210-001-0524-8 CrossRefGoogle Scholar
  26. Schaffer SW, Lombardini JB, Azuma J (2000) Interaction between the actions of taurine and angiotensin II. Amino Acids 18(4):305–318CrossRefPubMedGoogle Scholar
  27. Townsend DM, Deng M, Zhang L, Lapus MG, Hanigan MH (2003) Metabolism of Cisplatin to a nephrotoxin in proximal tubule cells. J Am Soc Nephrol 14(1):1–10CrossRefPubMedGoogle Scholar
  28. Yao X, Panichpisal K, Kurtzman N, Nugent K (2007) Cisplatin nephrotoxicity: a review. Am J Med Sci 334(2):115–124. doi: 10.1097/MAJ.0b013e31812dfe1e. 00000441-200708000-00006 [pii]CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2017

Authors and Affiliations

  • Masahiro Tsunekawa
    • 1
  • Shumin Wang
    • 1
  • Toshihiro Kato
    • 2
  • Takenori Yamashita
    • 3
  • Ning Ma
    • 1
    Email author
  1. 1.Graduate School of Health ScienceSuzuka University of Medical ScienceSuzukaJapan
  2. 2.Sport Medical CenterSuzukakaisei HospitalSuzukaJapan
  3. 3.Faculty of Health ScienceSuzuka University of Medical ScienceSuzukaJapan

Personalised recommendations